– Reuters
Phathom’s Vonoprazan Non-Inferior To Proton Pump Inhibitor For Esophagitis Inflammation
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) has announced data from the PHALCON-EE Phase 3 trial evaluating vonoprazan versus lansoprazole for erosive esophagitis (EE). …